GeneVentiv Therapeutics

About GeneVentiv Therapeutics

GeneVentiv Therapeutics is a pre-clinical gene therapy company dedicated to identifying, in-licensing, and developing transformative gene therapies. Their mission is to transform the lives of over 270,000 patients in the developed world by addressing significant unmet medical needs through innovative treatments.

Products & Services

GENV-HEM:A first-in-class gene therapy for all hemophilias, including inhibitor patients, designed to overcome durability issues associated with Factor VIII gene therapies.

GENV-002:A first-in-class gene editing therapy for both Infantile Onset (IOPD) and Late Onset (LOPD) forms of Pompe disease, offering lifelong enzyme production through stable integration of a functional GAA transgene.

Specialties

Gene Therapy Gene Editing Hemophilia Treatment Pompe Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: SBIR Grant T: - FT: SBIR Grant	A: 2500000 MR: - FA: $2.5 Million FAN: 2500000	D: 2024-04-16 FD: 2024-04-16	1 investors

SBIR Grant Latest

2024-04-16

$2.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Damon R. Race

President and CEO

R

Rob Limehouse

Board Member

S

Sylvia Fong

Consultant

D

David Lillicrap

Professor

S

Steven Pipe

Professor of Pediatrics and Pathology

L

Linda Couto

Consultant

View 9 more team members with Pro

Unlock Full Team Directory

Recent News